Evaluation – auswertungsanforderungen und wünsche (für das budget-modul)

Georg-August-Universität Göttingen, Bereich Humanmedizin Publikationen und Hochschulschriften 2005 Abteilung "Gynäkologie und Geburtshilfe"

Journalbeiträge
1. Eicke N, Günthert AR, Viereck V, Siebold D, Béhé M, Becker T, Emons G, Gründker C (2005) GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. EUR J ENDOCRINOL, 153(4): 605-12. 2. Emons G, Nieschlag E (2005) [Hormone replacement therapy. Interview by Wiebke Kathmann]. DEUT MED 3. Emons G, Fleckenstein G, Hinney B (2005) Hormonproduzierende Ovarialtumoren. GYNAKOLOGE, 38: 4. Girgert R, Schimming H, Körner W, Gründker C, Hanf V (2005) Induction of tamoxifen resistance in breast cancer cells by ELF electromagnetic fields. BIOCHEM BIOPH RES CO, 336(4): 1144-9. 5. Gründker C, Huschmand Nia A, Emons G (2005) Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. MOL CANCER THER, 4(2): 225-31. 6. Günthert AR, Gründker C, Olota A, Läsche J, Eicke N, Emons G (2005) Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. EUR J ENDOCRINOL, 153(4): 613-25. 7. Hinney B (2005) Immunologische Ursachen habitueller Aborte. Gyn Endokrin, 3: 25-31. 8. Hinney B, Emons G (2005) Update zur Hyperprolaktinämie. GYNAKOLOGE, 38: 310-314. 9. Hinney B, Wuttke W (2005) Hyperprolaktinämie: Stellenwert der Makroprolaktinämie. J Reproduktionsmed 10. O'toole SA, Dunn E, Sheppard BL, Sheils O, O'leary JJ, Wuttke W, Seidlova-Wuttke D (2005) Oestrogen regulated gene expression in normal and malignant endometrial tissue. MATURITAS, 51(2): 187-98. 11. Rath D, Töpfer-Petersen E, Michelmann HW, Schwartz P, Ebeling S (2005) Zona pellucida characteristics and sperm-binding patterns of in vivo and in vitro produced porcine oocytes inseminated with differently prepared spermatozoa. THERIOGENOLOGY, 63(2): 352-62. 12. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J EXP MED, 202(2): 271-81. 13. Schlüter G, Steckel M, Schiffmann H, Harms K, Viereck V, Emons G, Burfeind P, Pauer HU (2005) Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites. PRENATAL DIAG, 25(7): 574-6. 14. Schmidberger H, Hermann RM, Hess CF, Emons G (2005) Combination of anti-estrogenic therapy with radiation in breast cancer: simultaneous or sequential treatment? ONKOLOGIE, 28(4): 275-80. 15. Seidlová-Wuttke D, Christoffel J, Rimoldi G, Jarry H, Wuttke W (2005) Comparison of effects of estradiol with those of octylmethoxycinnamate and 4-methylbenzylidene camphor on fat tissue, lipids and pituitary hormones. TOXICOL APPL PHARM, -: -. 16. Seidlová-Wuttke D, Jarry H, Christoffel J, Rimoldi G, Wuttke W (2005) Effects of bisphenol-A (BPA), dibutylphtalate (DBP), benzophenone-2 (BP2), procymidone (Proc), and linurone (Lin) on fat tissue, a variety of hormones and metabolic parameters: a 3 months comparison with effects of estradiol (E2) in ovariectomized (ovx) rats. TOXICOLOGY, 213(1-2): 13-24. 17. Seidlová-Wuttke D, Jarry H, Pitzel L, Wuttke W (2005) Effects of estradiol-17beta, testosterone and a black cohosh preparation on bone and prostate in orchidectomized rats. MATURITAS, 51(2): 177-86. 18. Supornsilchai V, Svechnikov K, Seidlova-Wuttke D, Wuttke W, Söder O (2005) Phytoestrogen resveratrol suppresses steroidogenesis by rat adrenocortical cells by inhibiting cytochrome P450 c21-hydroxylase. HORM RES, 64(6): 280-6. 19. Svechnikov K, Supornsilchai V, Strand ML, Wahlgren A, Seidlova-Wuttke D, Wuttke W, Söder O (2005) Influence of long-term dietary administration of procymidone, a fungicide with anti-androgenic effects, or the phytoestrogen genistein to rats on the pituitary-gonadal axis and Leydig cell steroidogenesis. J ENDOCRINOL, 187(1): 117-24. 20. Thelen P, Scharf JG, Burfeind P, Hemmerlein B, Wuttke W, Ringert RH, Seidlová-Wuttke D (2005) Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer. CARCINOGENESIS, 26(8): 1360-7. 21. Tunn R, Schaer G, Peschers U, Bader W, Gauruder A, Hanzal E, Koelbl H, Koelle D, Perucchini D, Petri E, Riss P, Schuessler B, Viereck V (2005) Updated recommendations on ultrasonography in urogynecology. INT UROGYNECOL J, 16(3): 236-41. 22. Viereck V, Bader W, Krauß T, Oppermann M, Gauruder-Burmester A, Hilgers R, Hackenberg R, Hatzmann W, Emons G (2005) Intra-operative introital ultrasound in Burch colposuspension reduces post-operative complications. BJOG-INT J OBSTET GY, 112(6): 791-6. 23. Viereck V, Emons G, Wuttke W (2005) Black cohosh: just another phytoestrogen? TRENDS ENDOCRIN Georg-August-Universität Göttingen, Bereich Humanmedizin Publikationen und Hochschulschriften 2005 Abteilung "Gynäkologie und Geburtshilfe"

24. Viereck V, Gründker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC (2005) Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J CELL BIOCHEM, 96(6): 1244-53. 25. Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC (2005) Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J BONE MINER RES, 20(11): 2036-43. 26. von Witzendorff D, Ekhlasi-Hundrieser M, Dostalova Z, Resch M, Rath D, Michelmann HW, Topfer- Petersen E (2005) Analysis of N-linked glycans of porcine zona pellucida glycoprotein ZPA by MALDI-ToF mass spectrometry: a contribution to understanding zona pellucida structure. GLYCOBIOLOGY, 15 (5): 475-88. 27. Wilting J, Hawighorst T, Hecht M, Christ B, Papoutsi M (2005) Development of lymphatic vessels: tumour lymphangiogenesis and lymphatic invasion. CURR MED CHEM, 12(26): 3043-53. 28. Wuttke WH, Jarry H, Emons G, Viereck V, Seidlova-Wuttke D (2005) Phytoöstrogene Ersatz für die Hormonersatztherapie? Tägl Prax, 46: 513-521. Buchbeiträge
1. Emons G (2005) Therapie des Endometriumkarzinoms. In: Diedrich K, Felberbaum R, Polack S, Tauchert S (Hg.) 55. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2004. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Berlin, 522-531. 2. Gründker C, Naor Z, Millar RP, Seger R, Leung PC, Emons G (2005) Mechanisms of action of GnRH. In: Lunenfeld B (Hg.) GnRH Analogs. Martin Dunitz - Taylor and Francis Group Verlag, London, 1-33. 3. Hinney B, Wuttke W (2005) Ovarialfunktion. In: Thomas L (Hg.) Labor und Diagnose. TH-Books Verlagsgesellschaft, Frankfurt/Main, 1478-1492. 4. Wuttke W, Hinney B (2005) Störungen der weiblichen Gonaden. In: Schölmerich J (Hg.) Medizinische Therapie in Klinik und Praxis. Springer Verlag, Heidelberg, 625-650. Medizinische Dissertationen
1. Knobel A, Dr. med., Cellular characterisation and distribution of CD34 positive cells in abnormal wound healing. Dissertation Universität Göttingen 2005. 2. Niederkleine B, Dr. med., Raloxifen stimuliert die Produktion von Osteoprotegerin in humanen Osteoblasten. Dissertation Universität Göttingen 2005. 3. Schlotawa L, Dr. med., Stimulierung des Aktivierenden Proteins- 1 und der Jun- NH2- terminalen Kinase in Endometriumkarzinomzellen durch das Analogon des Luteinisierenden Hormon-Releasing-Hormons Triptorelin. Dissertation Universität Göttingen 2005. 4. Schneider P, Dr. med., Totale laparoskopische Hysterektomie (TLH) mit dem neuen Gewebeversiegelungssystem (LigaSure TM) in Kombination mit Vaginaltubus und Uterusmanipulator. Dissertation Universität Göttingen 2005. 5. von Bünau G, Dr. med., Introitussonographie des unteren Genitaltraktes vor und nach Kolposuspension. Dissertation Universität Göttingen 2005.

Source: http://www.umg.eu/de/media/forschung/publikationen_2005/pub_2005_gynaekologie_und_geburtshilfe.pdf

(microsoft word - crit\351rios_para_doa\347\343o_de_sangue_e_plaquetas_por_aferese.docx)

Critérios para doação de sangue e plaquetas por aférese O doador de sangue ou componentes deve ter idade de, no mínimo, 18 anos completos e, Peso : O peso mínimo para um candidato ser aceito para a doação é de 50 kg. Freqüência e intervalo entre as doações Para doação de sangue: 4 (quatro) doações anuais para os homens, e de 3 (três) doações anuais para O inte

05vc3835_324_403_pharm

PHARMACEUTICALS BRAND VS. GENERIC A.P.L.® Chorionic Gonadotropin Cevalin® Ascorbic Acid Erythromycin Topical Sol Chloromycetin® Inj Chloramphenicol Sodium Succ Achromycin V® Tetracycline Chlor-Trimeton® Tabs Chlorpheniramine Tabs Actifed® Triafed See Health & Beauty Aids Section See Health & Beauty Aids Section Chlor-Tri

Copyright 2014 Pdf Medic Finder